Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Serina Therapeutics, Inc. NASDAQ:SER Chief Scientific Officer Randall Moreadith sold 4,196 shares of common stock on July 29, 2025, for $6.50, totaling $27,274. The sale occurred as the stock shows a 7.87% gain over the past week, according to InvestingPro data. Following the transaction, Moreadith directly owns zero shares of the $56.28M market cap company.
On the same day, Moreadith exercised options to acquire 4,196 shares of Serina Therapeutics’ common stock at a price of $0.06, for a total value of $251. These options were fully vested and then sold. After these transactions, Moreadith directly owns 484,490 in stock options. With the company’s earnings report due on August 7, InvestingPro subscribers can access 11 additional key insights about Serina’s financial health and valuation metrics.
In other recent news, Serina Therapeutics, Inc. announced the advancement of SER-270, a once-weekly injectable treatment for tardive dyskinesia. This product candidate employs the company’s proprietary POZ polymer technology to facilitate weekly subcutaneous administration. The development of SER-270 aims to provide an alternative to daily oral medications, potentially benefiting patients who have difficulty adhering to a daily regimen. These recent developments highlight Serina’s ongoing efforts to innovate in the treatment of tardive dyskinesia. The company has not disclosed specific timelines or further details about the next steps in the development process. This advancement reflects Serina’s commitment to addressing the challenges faced by patients with tardive dyskinesia. The company’s approach could offer a new option for those struggling with medication adherence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.